#37degreesConference – IMATIS Fundamentum 6 – Lightweight ICT platform and ecosystem is released

Announcing upgraded #IMATIS Lightweight ICT system and Ecosystem with more than 250 web applications. The Lightweight ICT system offers the customers in the hospital, municipality and private citizen a wide range of application and solutions. The system provides applications for clinical use, support services, logistics, messaging, alarm, tasks management, queue- and patient flow management, data insights, key performance dashboards and performance metrics, solution for patient engagement, sensors, remote monitoring and much more. We’ve packed the healthcare ecosystem with new features and experiences for #Patients, #Doctors, Nurses, Service staff, Clinical staff and Administrative staff. You can now use your PC, Mac, tablet, iPad or Smart Phone to run any application from the ecosystem.

The IMATIS Lightweight ICT platform and ecosystem provides an open and secured environment for digitalizing healthcare. It effectively integrates and interconnects data and knowledge from a global and diverse network of healthcare stakeholders. The platform includes new tools for users to develop HTML5 and JavaScript applications, without writing code. Staff can build their own functionalities and make instant use of the applications right out of their personal or role-based devices. The new IMATIS version 6.0. runs from Cloud or can be installed on premises.

With the IMATIS Lightweight ICT platform and ecosystem the company visions to foster innovation and collaboration across the healthcare space.

Imatis has open API and integrates already to several international key vendors in the space. This includes HER and HIS vendors as Cerner, DXC, DIPS, Allscripts, and Others. The platform also integrates to PACS/RIS and lab stakeholders by using HL7 or FHIR. We also integrate alarm and nurse call from Ascom, Best, Merlon, Hill-Rom, Rauland. In the building and facility area we integrate Honeywell, Service Works Global, Johnson and Johnson, ABB, Siemens with others.

Imatis is a “game changer” that provides real-time experience of decision support in an innovative and user-friendly way. The Company is out of Norway with subsidiaries and Partners worldwide. Imatis solutions has a Cisco validated design, we are a Microsoft Gold Partner, and the Lightweight IMATIS Fundamentum solutions is Azure ready.

The New Østfold Hospital in Norway is the only EMRAN 6 (HIMSS) certified hospital in Nordic, they use the IMATIS Lightweight platform and several apps on smart phone, tablets, patient self service kiosk, signage screens, electronic whiteboards etc. The Helse Vest Region in Norway is currently implementing the plattform, and will go live shortly. St. Olavs Hospital og Oslo Municipality is currently live with the new version. Several contracts for upgrades is already signed, so stay tuned for updated information.

Hear the CEO of IMATIS during #37DegreesLifeScience Conference 2018! Join us there!

Source: https://www.linkedin.com/pulse/imatis-fundamentum-6-lightweight-ict-platform-morten-andresen/



About the connection between cancer and antibiotic resistance

Antibiotic resistance will ‘hit the bones’ of all the advances we have made in cancer treatment, says Secretary General Anne Lise Ryel on the Cancer Cancer Society’s blog . World Health Organization has determined that we are faced with a worldwide crisis that requires a comprehensive effort that the authorities can not solve solely. The ambition in the Jeløya platform is clear: Norway will be a global driver for coordinated efforts against antibiotic resistance. In Roche, our research teams work hard with the next generation of antibiotics – and also to create new and better diagnostic tests. We must learn to do things differently and we must all be flexible. Industry, health authorities and other actors. The learning curve will be steep. But work is absolutely necessary, as Rajji Mehdwan , managing director of Roche Norway, points out in this chronicle.

Antibiotic resistance is a topic in 37 Life science Conference program – last session, Day 2.

The company Roche is one of the sponsors of the event. Register now!


Antibiotikaresistens vil slå beina under alle de fremskrittene vi har gjort innenfor kreftbehandling, skriver generalsekretær Anne Lise Ryel på bloggen til Kreftforeningen (Norwegian Cancer Society). World Health Organization har fastslått at vi står overfor en verdensomspennende krise som krever en omfattende innsats som myndighetene ikke kan løse alene. Ambisjonen i Jeløya-plattformen er klar: Norge skal være en global pådriver for koordinert arbeid mot antibiotikaresistens. I Roche jobber våre forskerteam hardt med neste generasjon antibiotika – og også for å skape nye og bedre diagnostiske tester. Vi må lære å gjøre ting annerledes, og vi må alle være smidige. Industrien, helsemyndighetene og andre aktører. Læringskurven vil være bratt. Men arbeidet er helt nødvendig, slik Rajji Mehdwan, administerende direktør i Roche Norge, påpeker i denne kronikken.


The connection between cancer and antibiotic resistance.jpeg



Unsatisfied despite increased spending

Innovation in the health sector is weak despite a monetary spending of NOK 326 billion. This is the opinion of Abelia which is a branch of the Confederation of Norwegian Enterprise (NHO), who thinks that the Labour Party is more innovative than the Conservative Party and the Progress Party, currently in government.

They are standing in the exhibition hall at the 37 °C health tech conference in Stavanger, trying to convince passers-by of the blessings of the medical technology that they sell.

Air ambulance doctor Nils Petter Oveland has become an entrepreneur of Prometheus Medical Nordic in addition to his regular work. He no longer is satisfied with writing the research articles the hospital would like to have. He says that he has written five to six such articles, but that there are not many who read them.

– That’s why I became interested in this – because I wanted to influence the treatment of emergency patients. If we have success with our concepts, it will really affect how we treat the patients. That is something that can published instead of research articles.

Complaining about the lack of pace

Oveland is not alone in complaining about the pace of innovation in health care. Even though the spending has increased by 20 percent to NOK 326 billion over the last four years, the health minister Bent Høie (H) is also unhappy with the results. Last week, he stated to this newspaper that there are more pilot[projects]s in health care than in the airline companies Norwegian and SAS combined, but few of them take off and fly, since the healthcare system is not able to change.

Høie is ‘throwing stones in glasshouse’, says Abelia, the association for knowledge and technology companies in NHO.

“It is the minister himself who has the power make the changes,” says Tarje Bjørgum, head of climate and health in Abelia.

He presents whole list of objections. The health system lacks incentives to improve. Refund schemes incentivises yesterday’s solutions. Purchasing schemes do not promote innovation, and leaders are not incentivised to make improvements. The state is development solutions that the market can already offer. The state is also developing huge IT organizations that are not innovative. Norwegian healthcare companies are forced to seek customers abroad, because the home market is not open to innovation.






Minister of Health Bent Høie is tired of all the pilot projects

Minister of health, Bent Høie, visited the 37 °C Life Science Tech Conference on Tuesday, and met Håvard Bakke from Robot Norway.

Jostein Løvås



Minister of health, Bent Høie, believes that the Norwegian health care providers must soon embrace robots and information technology before the demographic wave of elderly people hit us with full force.

He is in the exhibition area at the health technology conference 37 °C in Stavanger and looks at a robot that Håvard Bakke from Robot Norway would like to sell to the health care providers.

Health Minister Bent Høie believes that the implementation of new technology in the health sector that he leads, must go much faster than today.

“I’m getting bored by all the pilot [project]s. I say that in the health service there are more pilots than in the airline companies Norwegian and SAS combined. The challenge is that there are very few of them that actually take off and fly because the health care sector is not able to adapt new technology and improve efficiency, “says Høie.

An example of a pilot project

For example, Høie refers to a pilot project in Stavanger, Oslo and Sarpsborg for the follow-up of chronically ill patients. One of the solutions is that chronically ill patients with lung disease are equipped with technology that allows for the patients to test themselves every day and that gives them feedback on their health conditions.

“It has led to a reduction in the use of hospitals and emergency services and home services of between 20 and 30 percent. It has improved the health of the patients. They say they have better health and better life. So it is a solution that both reduces the need for personnel and improves the health of the patients, “says Høie.

“Using this type of technology is not a pilot project anymore – it has been tested in a number of projects, showing positive results. I hope it will become the new norm.

Robots, not clammy hands

Some of the background for the conference here in Stavanger is that the oil city wants to grow in other sectors now as the oil industry is hit by crisis. Health is a priority area, something everyone from mayor Christine Sagen Helgø to top manager Tore Lærdal in Laerdal Medical talks about at the 37 °C conference in Stavanger Forum. Høie promises plenty of business opportunities for inventive oil technicians that will take on the healthcare industry.

“Yesterday’s solutions are not sustainable in terms of demographic development and disease development. It will require too many people. It is not possible to solve future health challenges in the same way as today, says Høie.

He believes robots for example can do routine tasks and give patients a sense of coping with life.



Source: https://www.dn.no/nyheter/2017/06/06/1726/Helse/-jeg-begynner-a-bli-lei-av-alle-pilotene


From #Clinical #Development to #Commercialization with a Single Source of Support

Many #healthcare companies choose #Europe for initial commercialization obtaining CE first prior to US launch due to reduced time and costs to the market.

Germany as the largest European healthcare market offers the perfect platform to gain local evidence and roll out the concept into the other EU markets. However, for foreign companies it is difficult to understand the critical regulatory and marketing roadmaps leading to a successful introduction of a product in Germany and Europe.

Foreign companies often require an experienced team to drive the process from clinical development to commercialization. Hannover Clinical Trial Center (HCTC) and its partner mediq Innovation Experts have established a streamlined program to support foreign medtech or biotech companies for their early entry into Germany and Europe. This program has already shown a successful implementation in terms of successful market entry of products from international companies.

Our hub provides a single source of support with a successful track record of more than 11 years experience and over 15 successful technology introductions. In the past, we have supported various international companies by:

  • Defining the business opportunity in Europe
  • Developing both the local clinical and business strategy
  • Determining and allocating key opinion leaders as well as clinical centers
  • Identifying, assigning, and supporting the best matching commercial partner


Meet with Us at #37°C Life Science Technology Conference & Exhibition

Jan Wende (mediq Innovation Experts) and Prof. Heiko von der Leyen (Hannover Clinical Trial Center) will be holding a panel together at 37 °C. We are looking forward to meeting you in Stavanger next week.

Mediq is a strategy and innovation consulting firm for the German, European and Israel markets. The company specializes in supporting strategic vision, clinical validation, market assessment and development, for companies focused on approval and commercialization of biomed/lifescience products into the European market.

Hannover Clinical Trial Center, founded in 2005, is an academic Contract Research Organization dedicated to provide clinical trial management services and early product development support. HCTC combines the clinical expertise and academic leadership of Hannover Medical School, a premier German university hospital, with the full-service operational capabilities of a contract research organization.



For more information and registrations:

Arne Hansson Rannestad 


Mob:       +47 940 10 236

Email:      arne@exceller.no

Web:        www.exceller.no

Skype:     arnehanssonrannestad
Development of the 37 ºC Life Science Technology Conference & Exhibition 6th-7th June 2017 Stavanger Forum in Norway is in partnership with Stavanger Forum and Kenes Exhibitions.


Please Register Today: Click Here

Order your exhibition space: Click Here

Enter into Partnership with us: Click Here





Cealtech: Ready for mass production of supermaterial

The Norwegian company Cealtech will start production of graphene – a material that can be important in everything from oil and gas to electronics, solar, medicine and spacecraft.

“It sounds like a material that will be a major revolution for new material technologies in the future,” says Prime Minister of Norway, Erna Solberg.

She newly met the Norwegian company that will soon mass-produce the super material graphene – known to be the thinnest and strongest material that has been created, with the potential to revolutionize a number of industries.

After the meeting Solberg said that it is important that we are able to develop new technologies.

“Norway is a country that is very good at material technology. It has been a priority since the early 80’s.

Super material

The material with a number of unusual characteristics, one of them being that it is 200 times stronger than steel, but very flexible, was first isolated by physicists Andre Geim and Konstantin Novoselov in 2004 – with the help of a fairly common piece of tape and graphite.

The two later won the Nobel Prize in Physics for their work with graphene.

The structure of the material is only one atom thick, based on carbon-shape graphite, with qualities that allow applications that span from industries such as oil and gas to electronics, solar, medicine and spacecraft.

– It’s a supermaterial. If we can find large-volume applications for graphene at sufficiently low prices, we will enter into a new age, says Lars Helge Helvig.

He is the largest owner and Acting General Manager of the Stavanger-based company Cealtech.

Prime Minister Erna Solberg met Cealtech in Oslo last Tuesday. From right: David Boyd at Caltech University, Technical Manager Marius Andreassen Jakobsen in Cealtech and Acting General Manager in Cealtech, Lars Helge Helvig.



Cancer in the family led Bjørn Rune Gjelsten into ownership in the cancer vaccine company Ultimovacs

Dagens Næringsliv

Cancer in the family led Bjørn Rune Gjelsten into ownership in the cancer vaccine company Ultimovacs. The company is now attracting interest from “big pharma” players and the company valuation is approaching 1 billion NOK.

Bjørn Rune Gjelsten had a personal reason to go into Ultimovacs. Now, the company that develops cancer vaccine based on immunotherapy can also prove to be a very good investment.

“The reason I entered was that I had cancer in my family. My father got sick and I got in touch with an environment around the Radium Hospital, says Gjelsten, who lost his father with prostate diagnosis a couple of years ago.

The company was in an early phase and faced a capital tire. So far, Gjelsten has invested NOK 30 million.

“Although I had a personal entrance, it’s no more money than it would be okay to lose,” he says.

As the development of the vaccine goes through different phases, the value of Ultimovacs also rises. Gjelsten Holding holds 35 percent of the shares.

“Now there is interest from large industrial players from big pharma and the Norwegian investor communities.

Strengthens the immune system

By means of immunotherapy, the body will be equipped to to fight the cancer cells.

One of the unanswered questions is how the vaccine works in combination with other medications in order to attack the cancer cells. This has aroused the interest of pharmaceutical companies with well-established cancer medicine. Immunotherapy and traditional medicine can attack the cancer from two angles, so-called duo treatment.

“The traditional medicine may weaken and passivate the cancer, while immunotherapy activates the immune system so that the body may attack the cancer by itself.

A real breakthrough will be if the vaccine can be used preventively against vulnerable groups.

– US authorities are now looking into whether the vaccine can be used proactively, Gjelsten adds.

Stock exchange for similar company

Ultimovacs is compared to another fast-growing immunotherapy company, Targovax, which has already reached a face value of NOK 1.1 billion on the stock exchange. The share price of Targovax has risen 120 percent since January last year.

Jonas Einarsson, Managing Director of the Radium Hospital Research Foundation, believes the two companies have clear resemblances and confirm that immunotherapy vaccines developed in Norway have become interesting for drug giants.

– The Vaccines that these two companies develop are made on the same platform, but have different types of attacks. I have to say that the clinical results are encouraging, but it takes time. I am an optimist for both companies, says Einarsson, who is in the board of both companies.


Ultimovacs will give a presentation in the Conference Program at 37 °C,

on June 6th.

Source: http://www.dn.no/nyheter/2017/05/15/2101/Industri/kreftvaksine-kan-gi-superavkastning-for-gjelsten

hannoverimpuls – your gateway to the 3rd biggest market in the world, Germany

hannoverimpuls, represented by Katharina Hanske, will exhibit at 37 °C. Germany is the 3rd biggest healthcare market in the world. hannoverimpuls offers a range of attractive services to support the expansion projects of companies. Our target: avoid risks upon entry to the market, and provide our clients with optimal individual and unbureaucratic relocation support. To put it another way: our job consists of simplifying as much as possible the establishment of your successful business in Hannover.

Register for 37 °C today: https://37degreescelsius.net

Check out hannoverimpuls, here.

15 of the 50 fastest growing #companies in the US Fortune 500 are #Healthcare

Since 1955, Fortune Magazine has released an annual list of the highest revenue generating companies in the US – the Fortune 500. In 2016 the US Fortune 500 companies generated $12 trillion in combined revenue accounting for over two-thirds of US GDP and employed 27 million people worldwide. Healthcare was the fastest growing sector 2014-2016.

37 ºC Life Science Technology Conference & Exhibition represents the Healthcare community in the Nordic region, bringing together local and global attendees.

At 37 ºC in Stavanger Norway, you will get to meet and interact the leaders from all over the world, representing firms and institutions such as Roche, Ultimovacs, Pfizer, IBM, TEKES, Biolink Group, Medpalett, Leerink, Norwegian Minister of Health, and more.

The Official Conference Program is now online: Click HERE

The Speakers can be seen here.

Ensure the Early Bird Conference & Exhibition Registration rates, which includes a Special 50% discounted price for Startups!